AbbVie ABBV Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $61.16B+8.6% | $56.33B+3.7% | $54.32B-6.4% | $58.05B+3.3% | ||
| $18.2B+7.7% | $16.9B-17.2% | $20.42B+17.2% | $17.41B-0.2% | ||
| $42.96B+8.9% | $39.43B+16.3% | $33.9B-16.6% | $40.64B+4.9% | ||
| 70.2%+0.2pp | 70%+7.6pp | 62.4%-7.6pp | 70%+1.0pp | ||
| $14.01B-5.0% | $14.75B+14.6% | $12.87B-15.6% | $15.26B+23.6% | ||
| $46.09B-2.4% | $47.2B+13.6% | $41.56B+4.1% | $39.94B+4.3% | ||
| $15.08B— | —— | $12.76B-29.6% | $18.12B+1.1% | ||
| 24.6%— | —— | 23.5%-7.7pp | 31.2%-0.7pp | ||
| $6.6B— | —— | $6.25B-53.6% | $13.48B+3.8% | ||
| $2.36B+515% | -$570M-141% | $1.38B-15.6% | $1.63B+13.3% | ||
| $4.23B-1.2% | $4.28B-12.0% | $4.86B-58.9% | $11.84B+2.5% | ||
| 6.9%-0.7pp | 7.6%-1.4pp | 9%-11.4pp | 20.4%-0.2pp | ||
| $2.36-1.7% | $2.40-12.1% | $2.73-58.7% | $6.61+2.5% | ||
| $23.28B— | —— | $21.45B-19.1% | $26.51B+0.3% | ||
| 38.1%— | —— | 39.5%-6.2pp | 45.7%-1.4pp | ||
| $15.08B— | —— | $12.76B-29.6% | $18.12B+1.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is AbbVie's revenue?
- AbbVie (ABBV) generated $62.8B in revenue over the trailing twelve months, up 9.5% year over year.
- Is AbbVie profitable?
- AbbVie reported $3.6B in net income over the trailing twelve months, a 5.8% net margin.
- What are AbbVie's profit margins?
- Gross margin is 70.7% and operating margin is 24.4%, with a 5.8% net margin.
- What is AbbVie's earnings per share?
- AbbVie's diluted EPS over the trailing twelve months is $2.03.
- Where does AbbVie's income statement data come from?
- Every line is extracted from AbbVie's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
